GNMSF - NantKwest COVID-19 Candidate And Other News: The Good Bad And Ugly Of Biopharma
- NantKwest announces initiation of second generation COVID-19 vaccine candidate.
- Protagonist Therapeutics receives orphan drug status for PTG-300.
- Genmab reports positive data from Phase 2 CASSIOPEIA study.
For further details see:
NantKwest COVID-19 Candidate, And Other News: The Good, Bad And Ugly Of Biopharma